Amicus Therapeutics Inc (FOLD.OQ)
10 Dec 2013
|Market Cap (Mil.):||$103.73|
|Shares Outstanding (Mil.):||49.63|
Nov 21 - Amicus Therapeutics Inc : * JP Morgan cuts to neutral from overweight For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on Reuters 3000Xtra users, double-click Thomson ONE users, type in RT/RCH/US For a summary of rating and price target changes on Canadian companies: Reuters Eikon users, click on Reuters 3000Xtra users, double-click Thomson ONE users, type in RT/RCH/CA
Nov 20 - Amicus Therapeutics Inc : * Amicus has acquired Callidus Biopharma * Under deal terms, Callidus Shareholders will get $15 million in shares of co
Nov 20 - Amicus Therapeutics Inc : * Amicus Therapeutics and GSK announce revised fabry agreement * Says acquires full rights to global drug development, regulatory and
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Amicus Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.